Does Alcohol Consumption During Multidrug-resistant Tuberculosis Treatment Affect Outcome?. A Population-based Study in Kerala, India
Overview
Authors
Affiliations
Rationale: India reports the largest number of multidrug-resistant tuberculosis cases in the world; yet, no longitudinal study has assessed factors related to treatment outcomes under programmatic conditions in the public sector.
Objectives: To describe demographic, clinical, and risk characteristics associated with treatment outcomes for all patients with multidrug-resistant tuberculosis registered in the Revised National Tuberculosis Control Programme, Kerala State, India from January 1, 2009 to June 30, 2010.
Methods: Cox regression methods were used to calculate adjusted hazard ratios with 95% confidence intervals (CIs) to assess factors associated with an unsuccessful treatment outcome.
Measurements And Main Results: Of 179 patients with multidrug-resistant tuberculosis registered, 112 (63%) had successful treatment outcomes (77 bacteriologically cured, 35 treatment completed) and 67 (37%) had unsuccessful treatment outcomes (30 died, 26 defaulted, 9 failed treatment, 1 stopped treatment because of drug-related adverse events, and 1 developed extensively drug-resistant tuberculosis). The hazard for unsuccessful outcome was significantly higher among patients who consumed alcohol during treatment (adjusted hazard ratio, 4.3; 95% CI, 1.1-17.6) than those who did not. Persons who consumed alcohol during treatment, on average, missed 18 more intensive-phase doses (95% CI, 13-22) than those who did not. Although many patients had diabetes (33%), were ever smokers (39%), or had low body mass index (47%), these factors were not associated with outcome.
Conclusion: Overall treatment success was greater than global and national averages; however, outcomes among patients consuming alcohol remained poor. Integration of care for multidrug-resistant tuberculosis and alcoholism should be considered to improve treatment adherence and outcomes.
VidyaRaj C, Vadakunnel M, Mani B, Anbazhagi M, Pradhabane G, Venkateswari R Sci Rep. 2025; 15(1):8290.
PMID: 40065047 PMC: 11893790. DOI: 10.1038/s41598-025-92613-5.
Sumana M, Saraswathi S, Mukhopadhyay A, Debata I, Ranganath T J Family Med Prim Care. 2024; 13(8):3129-3134.
PMID: 39228632 PMC: 11368369. DOI: 10.4103/jfmpc.jfmpc_23_24.
Jhaveri T, Jhaveri D, Galivanche A, Lubeck-Schricker M, Voehler D, Chung M PLoS Med. 2024; 21(5):e1004409.
PMID: 38805509 PMC: 11166313. DOI: 10.1371/journal.pmed.1004409.
Adherence to Epilepsy's Medical Recommendations.
Jopowicz A, Piechal A, Bronisz E, Kurkowska-Jastrzebska I Brain Sci. 2024; 14(3).
PMID: 38539643 PMC: 10968293. DOI: 10.3390/brainsci14030255.
Peng A, Kong X, Liu S, Zhang H, Xie L, Ma L Sci Rep. 2024; 14(1):6814.
PMID: 38514736 PMC: 10957874. DOI: 10.1038/s41598-024-57446-8.